Brainsway (NASDAQ:BWAY) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Brainsway (NASDAQ:BWAY) issued its quarterly earnings results on Wednesday. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04, Zacks reports. The company had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.54 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%.

Brainsway Stock Performance

Shares of Brainsway stock traded up $0.27 on Thursday, hitting $16.87. The stock had a trading volume of 82,251 shares, compared to its average volume of 165,120. The stock has a 50 day moving average of $15.08 and a 200 day moving average of $14.33. Brainsway has a twelve month low of $6.26 and a twelve month high of $17.40. The firm has a market capitalization of $676.99 million, a P/E ratio of 48.20 and a beta of 1.24.

Analyst Ratings Changes

Several brokerages recently weighed in on BWAY. New Street Research restated a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a research report on Tuesday, July 21st. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Brainsway in a research note on Friday, July 17th. BTIG Research increased their target price on shares of Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.33.

Hedge Funds Weigh In On Brainsway

A number of hedge funds have recently modified their holdings of BWAY. Man Group plc increased its holdings in Brainsway by 4.5% in the fourth quarter. Man Group plc now owns 18,027 shares of the company’s stock valued at $343,000 after purchasing an additional 782 shares during the period. Trexquant Investment LP bought a new position in Brainsway during the 4th quarter worth $245,000. Royal Bank of Canada lifted its holdings in Brainsway by 1,145.9% during the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after buying an additional 7,735 shares during the period. ARK Investment Management LLC acquired a new position in Brainsway during the 4th quarter worth about $2,422,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Brainsway by 2.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock valued at $490,000 after buying an additional 589 shares during the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

Trending Headlines about Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: BrainsWay reported record second-quarter 2026 revenue of $17.1 million, up 35% year over year, while EPS of $0.14 exceeded the $0.10 analyst consensus. Revenue also surpassed expectations of $16.54 million. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: The company guided for fiscal-year 2026 revenue of $68.0 million to $70.0 million, above the $67.8 million consensus estimate. The stronger outlook supports expectations for continued commercial growth. BrainsWay Q2 2026 Earnings Call Transcript
• Positive Sentiment: BTIG Research raised its price target to $20 from $18 and reiterated a Buy rating, implying additional upside based on the company’s earnings momentum. Brainsway Price Target Raised at BTIG
• Positive Sentiment: The strong earnings report helped push BWAY to a new one-year high, signaling continued investor enthusiasm for its financial performance. Brainsway Sets New One-Year High Following Strong Earnings
• Neutral Sentiment: Reported short interest was listed at zero shares, providing no meaningful indication of short-seller pressure; the figure may reflect incomplete or anomalous data.
• Negative Sentiment: Zacks Research downgraded BrainsWay from Strong Buy to Hold. The change could temper bullish sentiment after the recent rally, despite the company’s stronger results. Zacks Research

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.